ERBB2 and breast carcinoma: HER2 is overexpressed in 25–30% of breast cancers, and drugs targeting this receptor (such as humanised recombinant monoclonal antibody Herceptin) have been developed for the treatment of the subset of HER2-positive breast cancers.